Combining the principles of evolution with artificial intelligence (AI), scientists have proposed a new way to predict the chance of prostate cancer returning. In a recent study, they harnessed ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

"Our findings open avenues for biomarkers of therapy response and acquired drug resistance to help guide clinical decisions in individual patients with metastatic prostate cancer throughout the course ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about navigating treatment option in prostate cancer. Advancements in prostate ...

The ASCO theme "The Science and Practice of Translation: Improving Cancer Outcomes Worldwide," selected by 2025-2026 ...

A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong ...

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research ...

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...

Advances in radiotherapy are rapidly transforming how prostate cancer is treated, offering patients more precise, less invasive options that can fit more easily around everyday life ...

Extracellular vesicles shed by prostate cancer cells to the bloodstream contain tumor-derived material that can be used as biomarkers of therapy response and resistance in patients with metastatic ...